SCHEMBL17401008

SCHEMBL17401008

COCCOCCn1cc(-c2ccccc2)nc1[C@@H]1CCCN1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.41
PDE10A Q9Y233 5/20 0.36
TLR8 Q9NR97 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.35
NFKB1 P19838 1/20 0.35
RAB9A P51151 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
HRH1 P35367 2/20 0.33
PDCD1LG2 Q9BQ51 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
HPGD P15428 1/20 0.33
RPS6KB1 P23443 2/20 0.33
AKT1 P31749 2/20 0.33
OGFRL1 Q5TC84 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17401023 0.94 TAAR1 (0.44) TAAR1PDE10ATLR8PDCD1LG2CD274
SCHEMBL17401024 0.81 TAAR1 (0.44) TAAR1PDE10ATLR8KDM4EALDH1A1
SCHEMBL17401022 0.79 RPS6KB1 (0.46) TAAR1PDE10ARPS6KB1AKT1
SCHEMBL17396051 0.77 TAAR1 (0.52) TAAR1PDE10AOGFRL1
SCHEMBL17396052 0.77 TAAR1 (0.52) TAAR1PDE10AOGFRL1
SCHEMBL17401013 0.77 PDE10A (0.44) TAAR1PDE10ARPS6KB1AKT1
SCHEMBL17401014 0.71 RPS6KB1 (0.42) TAAR1RPS6KB1AKT1
SCHEMBL17401018 0.70 RPS6KB1 (0.44) TAAR1RPS6KB1AKT1
SCHEMBL17401012 0.70 CHRNA7 (0.46) TAAR1PDE10ATLR8SMN1; SMN2KDM4E
SCHEMBL17401016 0.70 RPS6KB1 (0.44) RPS6KB1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9868758-B2 Betulinic proline imidazole derivatives as HIV inhibitors HETERO LABS LIMITED (IN) 2018-01-16 US disclosed
US-9868758-B2 Betulinic proline imidazole derivatives as HIV inhibitors HETERO LABS LIMITED (IN) 2018-01-16 US disclosed
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2017-05-11 US disclosed
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2017-05-11 US disclosed
WO-2016001820-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2016-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS BET1, PRR12, IMPA1 TAAR1 3391/4885PDE10A 2228/4885TLR8 2069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.